Monopar Therapeutics (MNPR) PT Lowered to $52 at Brookline Capital Markets
Tweet Send to a Friend
Brookline Capital Markets analyst Kemp Dolliver lowered the price target on Monopar Therapeutics (NASDAQ: MNPR) to $52.00 (from $58.00) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
